

AssayMax™ Human Factor XI ELISA Kit

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419 www.assaypro.com

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

Assay Summary

Step 1. Add 50 μl of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μ l of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 20 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key



Consult instructions for use.

Assay Template

12								
11								
10								
6								
∞								
7								
9								
.c								
4								
ю								
2								
1								
	Ą	В	3	Q	3	Ŧ	9	I

AssayMax™ Human Factor XI (Factor 11) ELISA Kit

Catalog No. EF1011-1
Sample insert for reference use only

Introduction

Human coagulation factor XI (FXI), also called plasma thromboplastin antecedent, is a serine protease important for initiating the contact activation or intrinsic pathway of blood coagulation. Factor XI is present in plasma as a homodimer zymogen consisting of two identical polypeptide chains of 607 amino acids and 80 kDa each. Factor XI circulates in normal plasma at a 5 µg/ml concentration. It is activated to form factor XIa, not only by factor XIIa through the contact pathway but also by thrombin, through feedback activation linked to tissue factor or extrinsic pathway. Factor XIa, in turn, cleaves factor IX and triggers a cascade event converting fibrinogen to a stable cross-linked fibrin clot formation (1-3). Factor XI also plays a role in the prevention of clot lysis from fibrinolysis (4). Congenital factor XI deficiency is accompanied by mild and injury-related bleeding. Severe factor XI deficiency is linked to low occurrence of ischemic stroke or venous thrombosis (5). In contrast, elevated factor XI activity is a risk factor for stroke, venous thrombosis, and coronary artery disease (6-8). Factor XI is a new target for the treatment and prevention of thromboembolism.

Principle of the Assay

The AssayMax™ Human Factor XI ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of factor XI in human plasma and serum samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures human factor XI in approximately 4 hours. A polyclonal antibody specific for human factor XI has been pre-coated onto a 96-well microplate with removable strips. Factor XI in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human factor XI, which is recognized by a streptavidin-peroxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- This product is for Research Use Only and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate), as instructed, prior to running the assay.
- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human Factor XI Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human factor XI.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human Factor XI Standard: Human factor XI in a buffered protein base, calibrated against WHO 1st International Standard (100 ng, lyophilized).
- Biotinylated Human Factor XI Antibody (50x): A 50-fold concentrated biotinylated polyclonal antibody against human factor XI (120 µl).
- **EIA Diluent Concentrate (10x):** A 10-fold concentrated buffered protein base (30 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 μl).
- Chromogen Substrate (1x): A stabilized peroxidase chromogen substrate tetramethylbenzidine (7 ml).
- **Stop Solution (1x):** A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (11 ml).

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store Standard, SP Conjugate, and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.

Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

- Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. A 600-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- **Serum:** Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes and remove serum. A 600-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	Guidelines for Dilutions of 100-fold or Greater				
	(for reference only; please follow the insert for specific dilution suggested)				
	100x		10000x		
A)	4 μl sample : 396 μl buffer (100x)	A)	4 μl sample : 396 μl buffer (100x)		
	= 100-fold dilution	B)	4 μl of A : 396 μl buffer (100x)		
			= 10000-fold dilution		
	Assuming the needed volume is less than		Assuming the needed volume is less than		
	or equal to 400 μl.		or equal to 400 μl.		
	1000x		100000x		
A)	4 μl sample : 396 μl buffer (100x)	A)	4 μl sample : 396 μl buffer (100x)		
B)	24 μl of A : 216 μl buffer (10x)	B)	4 μl of A : 396 μl buffer (100x)		
	= 1000-fold dilution	C)	24 μl of B : 216 μl buffer (10x)		
			= 100000-fold dilution		
	Assuming the needed volume is less than		Assuming the needed volume is less than		
	or equal to 240 μl.		or equal to 240 μl.		

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- **EIA Diluent Concentrate (10x):** Dilute the EIA Diluent Concentrate 10-fold with reagent grade water to produce a 1x solution. When diluting the concentrate, make sure to rinse the bottle thoroughly to extract any precipitates left in the bottle. Mix the 1x solution gently until the crystals have completely dissolved. Store for up to 30 days at 2-8°C.
- Human Factor XI Standard: Reconstitute the Human Factor XI Standard (100 ng, 20 mIU) with 1 ml of EIA Diluent to generate a 100 ng/ml (20 mIU/ml) standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (100 ng/ml) 2-fold with equal volume of EIA Diluent to produce 50, 25, 12.5, 6.25, 3.125, and 1.563 ng/ml solutions. EIA Diluent serves as the zero standard (0 ng/ml). Any remaining stock solution should be stored at -20°C and used within 30 days. Avoid repeated freeze-thaw cycles.

Standard Point	Dilution	[FXI] (ng/ml)	[FXI] (mIU/ml)
P1	1 part Standard + 1 part EIA Diluent	50	10
P2	1 part P1 + 1 part EIA Diluent	25	5.0
P3	1 part P2 + 1 part EIA Diluent	12.5	2.5
P4	1 part P3 + 1 part EIA Diluent	6.25	1.25
P5	1 part P4 + 1 part EIA Diluent	3.125	0.625
P6	1 part P5 + 1 part EIA Diluent	1.563	0.313
P7	EIA Diluent	0.0	0.0

- Biotinylated Human Factor XI Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with EIA Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 20fold with reagent grade water to produce a 1x solution. When diluting
 the concentrate, make sure to rinse the bottle thoroughly to extract any
 precipitates left in the bottle. Mix the 1x solution gently until the crystals
 have completely dissolved.
- SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the
 desired amount of the conjugate 100-fold with EIA Diluent to produce a
 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them
 immediately to the foil pouch with desiccants inside. Reseal the pouch
 securely to minimize exposure to water vapor and store in a vacuum
 desiccator.
- Add 50 µl of Human Factor XI Standard or sample to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash the microplate manually or automatically using a microplate washer. Invert the plate and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If washing manually, wash five times with 200 μl of Wash Buffer per well. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a microplate washer, wash six times with 300 μl of Wash Buffer per well; invert the plate and hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human Factor XI Antibody to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate in ambient light for 20 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections. Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data


The typical data is provided for reference only. Individual laboratory
means may vary from the values listed. Variations between laboratories
may be caused by technique differences.

Standard Point	ng/ml	OD	Average OD
P1	50	2.088	2.135
ΓI	30	2.182	2.133
P2	25	1.591	1.622
12	23	1.653	1.022
P3	12.5	1.051	1.030
13	12.5	1.009	1.050
P4	6.25	0.616	0.620
1 7	0.23	0.624	0.020
P5	3.125	0.393	0.381
13	5.125	0.369	0.361
P6	1.563	0.263	0.256
10	1.505	0.249	0.230
P7	0.0	0.128	0.123
. ,	0.0	0.118	0.125
Sample: Pooled Normal		0.728	0.742
Sodium Citrate	Plasma (600x)	0.756	0.742
Sample: Poo	oled Normal	0.936	0.923
Serum	(600x)	0.910	0.923


Standard Curve

 The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Human Factor XI Standard Curve



Human Factor XI Standard Curve



Reference Value

- Normal human factor XI plasma and serum levels range from 3 8 μg/ml.
- Plasma and serum samples from healthy adults were tested (n=20). On average, human factor XI level was 5433 ng/ml.

Sample	n	Average Value (ng/ml)
Pooled Normal Plasma	10	4650
Pooled Normal Serum	10	6215

Performance Characteristics

- Kit standard has been calibrated against WHO International Standard.
- The minimum detectable dose of human factor XI as calculated by 2SD from the mean of a zero standard was established to be 0.75 ng/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

	Intra	-Assay Pred	ision	Inter	-Assay Pred	ision
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	3.1%	2.5%	3.7%	9.6%	9.3%	10.9%
Average CV (%)	3.1%				9.9%	

Spiking Recovery

 Recovery was determined by spiking one plasma and one serum sample with different factor XI concentrations.

Sample	Unspiked Sample (ng/ml)	Spiking Value (ng/ml)	Expected	Observed	Recovery (%)
		5.574	12.933	11.879	92%
Plasma	7.359	3.044	10.403	9.557	92%
		1.778	9.137	8.346	91%
		5.574	15.339	13.639	89%
Serum	9.765	3.044	12.809	11.842	92%
		1.778	11.543	10.348	90%
	91%				

Linearity

Plasma and serum samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)					
Sample Dilution	Plasma	Serum			
300x	94%	95%			
600x	99%	101%			
1200x	105%	106%			

Cross-Reactivity

Species	Cross-Reactivity (%)
Canine	None
Bovine	None
Equine	None
Monkey	None
Mouse	None
Rat	None
Swine	None
Rabbit	None
Protein	Cross-Reactivity (%)
Human Factor XIa	100%

 No significant cross-reactivity observed with human factor I (fibrinogen), factor II (prothrombin), factor III (tissue factor), factor V, factor VII, factor VIII, factor IX, factor X, factor XII, factor XIII, factor XIV (protein C), and VWF proteins.

Troubleshooting

Issue	Causes	Course of Action
	Use of improper components	Check the expiration date listed before use. Do not interchange components from different lots.
_	Improper wash step	Check that the correct wash buffer is being used. Check that all wells are empty after aspiration. Check that the microplate washer is dispensing properly. If washing by pipette, check for proper pipetting technique.
cisio	Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.
Low Precision	Inconsistent volumes loaded into wells	 Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.
	Insufficient mixing of reagent dilutions	 Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.
	Improperly sealed microplate	 Check the microplate pouch for proper sealing. Check that the microplate pouch has no punctures. Check that three desiccants are inside the microplate pouch prior to sealing.

gnal	Microplate was left unattended between steps	 Each step of the procedure should be performed uninterrupted.
ı∑	Omission of step	 Consult the provided procedure for complete list of steps.
Unexpectedly Low or High Signal Intensity	Steps performed in incorrect order	Consult the provided procedure for the correct order.
દ જ	Insufficient amount of	Check pipette calibration.
ly Low or Intensity	reagents added to wells	Check pipette for proper performance.
_ ≥ ⊆	Wash step was skipped	 Consult the provided procedure for all wash steps.
E E	Improper wash buffer	 Check that the correct wash buffer is being used.
e C	Improper reagent	 Consult reagent preparation section for the correct
χ	preparation	dilutions of all reagents.
ne	Insufficient or	Consult the provided procedure for correct incubation
>	prolonged incubation	time.
-	periods	
Deficient Standard Curve Fit	Non-optimal sample dilution	 Sandwich ELISA: If samples generate OD values higher than the highest standard point (P1), dilute samples further and repeat the assay. Competitive ELISA: If samples generate OD values lower than the highest standard point (P1), dilute samples further and repeat the assay. User should determine the optimal dilution factor for samples.
anda	Contamination of reagents	 A new tip must be used for each addition of different samples or reagents during the assay procedure.
nt Sta	Contents of wells evaporate	 Verify that the sealing film is firmly in place before placing the assay in the incubator or at room temperature.
Deficie	Improper pipetting	 Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.
	Insufficient mixing of reagent dilutions	Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.

References

- (1) Fujikawa K et al. (1986) Biochemistry. 25:2417-2424.
- (2) Asakai R et al. (1987) Biochemistry. 26:7221-7228.
- (3) Samuel D et al. (2007) Proc Natl Acad Sci USA. 104:15693-15698.
- (4) von dem Borne PA et al. (1995) Blood. 86:3035-3042.
- (5) Salomon O et al. (2008) Blood. 111:4113-4117.
- (6) Yang DT et al. (2006) Am J Clin Pathol. 126:411-415.
- (7) Eichinger S et al. (2004) Blood. 103:3773-3776.
- (8) Berliner JI et al. (2002) Thromb Res. 107:55-60.

Version 4.5